Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
“The European Commission approval of Povofortay marks an important milestone for
The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2
Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and durable efficacy. Both studies met the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50, ≥50% reduction from baseline in the total abscess and inflammatory nodule count [AN count] without an increase in abscess or draining tunnel count relative to baseline) versus placebo at Week 12, at both studied doses (45 mg and 75 mg) in the overall intent-to-treat (ITT) population. Consistent efficacy was observed in the post-anti-TNF population, which is reflected in the
The overall safety profile of Povofortay over 54 weeks was consistent with previously reported data; both doses were well tolerated, with no new or unexpected safety signals. The most frequent TEAEs across both studies and doses were acne, nasopharyngitis and upper respiratory tract infections with most events reported as mild or moderate.2
“HS is a challenging disease to manage, and many patients struggle with the significant burden that affects many aspects of their lives,” said Professor Dr.
The
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses and draining tunnels that can lead to irreversible tissue destruction and scarring. Given the debilitating nature of the condition, it can have a profoundly negative effect on patients’ quality of life.2,4 Overactivity of the JAK/STAT signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS.3 HS affects approximately 1% of the global population.4
About Povofortay® (povorcitinib)
Povofortay (povorcitinib) is an oral small-molecule JAK1 selective inhibitor approved in
A New Drug Application (NDA) for povorcitinib in adults with moderate to severe HS is under review by the
Povofortay is a registered trademark of
For more information, see the Povofortay SmPC.
About Incyte®
Incyte is redefining what is possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation potential medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Povofortay’s potential contribution to Incyte’s future growth; Povofortay’s potential to become an important new treatment option for patients with HS and help address unmet needs in the treatment of HS; the potential for regulatory approval of povorcitinib in the U.S.; the timing of any such approval and commercial launch, including the potential for U.S. approval and launch in the first quarter of 2027; the potential commercial availability and success of Povofortay; the further development of povorcitinib in additional indications; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; actions of regulatory agencies, which may affect the timing and scope of marketing approval; the efficacy or safety of Incyte’s products; Incyte’s ability to achieve commercial success for its marketed products and product candidates, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended September 30, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.
| ____________________________ | |
|
1 |
|
|
2 |
Porter ML, Martorell A, Sayed CJ, Bechara FG, |
|
3 |
Jemec GBE, Villumsen B, van Straalen KR, van der Zee HH, Valiukevičienė S, Tzellos T, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment. J Eur Acad Dermatol Venereol. 2026; 00: 1–20. https://doi.org/10.1111/jdv.70638. |
|
4 |
Bouazzi D, Nielsen SM, Hagan PG, et al. Prevalence of hidradenitis suppurativa: A meta-analysis of Global Hidradenitis Suppurativa Atlas studies. JAMA Dermatol. 2025;161(10):1022-1028. https://doi.org/10.1001/jamadermatol.2025.2373 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116905792/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: